➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
McKinsey
Express Scripts
Colorcon

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022383


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022383 describes ARCAPTA NEOHALER, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the ARCAPTA NEOHALER profile page.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. One supplier is listed for this compound. Additional details are available on the indacaterol maleate profile page.
Summary for 022383
Tradename:ARCAPTA NEOHALER
Applicant:Novartis
Ingredient:indacaterol maleate
Patents:5
Generic Entry Opportunity Date for 022383
Generic Entry Date for 022383*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022383
Mechanism of ActionAdrenergic beta2-Agonists
Suppliers and Packaging for NDA: 022383
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383 NDA Sunovion Pharmaceuticals Inc. 63402-675 63402-675-06 1 BLISTER PACK in 1 CARTON (63402-675-06) > 6 CAPSULE in 1 BLISTER PACK (63402-675-02)
ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383 NDA Sunovion Pharmaceuticals Inc. 63402-675 63402-675-30 5 BLISTER PACK in 1 CARTON (63402-675-30) > 6 CAPSULE in 1 BLISTER PACK (63402-675-01)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrengthEQ 75MCG BASE
Approval Date:Jul 1, 2011TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Feb 25, 2025Product Flag?YSubstance Flag?YDelist Request?
Patented Use:THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
Patent:  Start TrialPatent Expiration:Jun 2, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
Patent:  Start TrialPatent Expiration:Oct 11, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022383

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011   Start Trial   Start Trial
Novartis ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011   Start Trial   Start Trial
Novartis ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.